

# GlaxoSmithKline PLC

08:27 09 Oct 2019

## GSK recalls heartburn drug over carcinogen risk

GlaxoSmithKline PLC (LON:GSK) is recalling heartburn drug Zantac in "all markets" after being contacted by the authorities over a possible carcinogen contamination.

The pharma company told Proactive all unexpired stock of four types of the drug was going to be removed from retailers as a "precautionary action" and investigations were ongoing.

**READ:** Walgreens and Rite Aid join CVS Health in discontinuing sales of popular heartburn drug Zantac

The UK Medicines and Healthcare products Regulatory Agency (MHRA) advised patients to continue taking their medication if the health risk of discontinuing it was greater than the potential risk presented by the contaminant.

The US Food and Drug Administration (FDA) announced last month that some stocks of Zantac, sold generically as ranitidine, possibly contained a nitrosamine impurity called N-nitrosodimethylamine (NDMA) at low levels.

NDMA is a known environmental contaminant, classified as a probable human carcinogen, and is found in water and foods, including meats, dairy products, and vegetables.

The American authority alerted healthcare professionals and patients to voluntarily recall over-the-counter ranitidine tablets, while it keeps carrying out tests to assess their potential impact. Not all ranitidine products in the US have been recalled.

GSK shares were up 0.98% to 1,729.8p in mid-morning.

--Adds company's comment--

**Price:** 1658.2

**Market Cap:** £83.18 billion

### 1 Year Share Price Graph



### Share Information

**Code:** GSK

**Listing:** LSE

<b>52 week</b>	<b>High</b>	<b>Low</b>
	2147.34	1485.2

**Sector:** Pharma & Biotech

**Website:** [www.gsk.com](http://www.gsk.com)

### Company Synopsis:

*GlaxoSmithKline supplies an estimated seven per cent of the world's pharmaceutical market and has six major disease areas - asthma, virus control, infections, mental health, diabetes and digestive conditions.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related

products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.